Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.67 |
| ▸ | ACE | P12821 | 4/20 | 0.59 |
| ▸ | CPA1 | P15085 | 1/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987345 | 1.00 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL29761659 | 1.00 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL29408691 | 1.00 | MME (0.67) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL30011266 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL31025643 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL29527395 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL30011237 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL30011197 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| SCHEMBL31025645 | 0.97 | MME (0.64) | MMEACECPA1ACE2SLC7A5 | |
| Trifluoroacetic Acid SCHEMBL31675100 | 0.94 | MME (0.60) | MMEACECPA1ACE2SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250121026-A1 | COMPOSITIONS AND METHODS FOR TREATING FIBROSIS | CEDARS-SINAI MEDICAL CENTER (US) | 2025-04-17 | — | — | US | claimed |
| WO-2025043563-A1 | PEPTIDE TARGETING SOMATOSTATIN RECEPTOR, DRUG CONJUGATE AND USE THEREOF | 主流源生物科技(上海)有限公司 | 2025-03-06 | — | — | WO | claimed |
| US-20240336654-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Universität Zürich (CH) | 2024-10-10 | — | — | US | claimed |
| CN-118660707-A | Supermolecule self-assembly system | 北京睿创康泰医药研究院有限公司 | 2024-09-17 | — | — | CN | claimed |
| EP-4380689-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Basilea Pharmaceutica International AG, Allschwil (CH) | 2024-06-12 | — | — | EP | claimed |
| CN-118043339-A | Antimicrobial peptidomimetics | 巴斯利尔药物阿尔施维尔国际股份公司 | 2024-05-14 | — | — | CN | claimed |
| CN-116333949-A | Engineered bacterium for in-situ synthesis of melanin by tumor and application thereof | 华中科技大学 | 2023-06-27 | — | — | CN | claimed |
| CN-110655553-B | ACE inhibitory peptide derived from sesame, preparation method and application thereof in preparation of antihypertensive drugs | 河南省农业科学院 | 2023-02-21 | — | — | CN | claimed |
| WO-2023012319-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2023-02-09 | — | — | WO | claimed |
| US-11547738-B2 | Compositions and methods for treating fibrosis | CEDARS-SINAI MEDICAL CENTER (US) | 2023-01-10 | — | — | US | claimed |
| US-20260117070-A1 | NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| US-20260069707-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES | HALOZYME, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4687960-A1 | METHODS OF HEMATOPOIETIC PRECURSOR CELLS MOBILIZATION | BioLineRx Ltd. (IL) | 2026-02-11 | — | — | EP | disclosed |
| US-20250346589-A1 | RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS | UNIV ERASMUS MED CT ROTTERDAM (NL) | 2025-11-13 | — | — | US | disclosed |
| WO-2025224720-A1 | METHODS OF SELECTING TREATMENT REGIMEN AGAINST SOLID TUMORS | BIOLINERX LTD. (IL) | 2025-10-30 | — | — | WO | disclosed |
| CN-101235081-A | Method for preparing oxytocin | WUXI KAILI PHARMACEUTICAL CO L (CN) | 2008-08-06 | — | — | CN | disclosed |
| WO-2005027713-A2 | COMPOSITIONS, SPLICE VARIANTS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004053077-A2 | COMPOSITIONS,SPLICE VARIANTS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004013311-A2 | COMPOSITIONS AND METHODS RELATING TO OVARIAN SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003060121-A9 | COMPOSITIONS AND METHODS RELATING TO GASTRIC SPECIFIC GENES AND PROTEINS | DIADEXUS INC (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346589-A1 | RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS | SSTR2, SSTR5, SSTR1 | MME 223/4885ACE 1766/4885CPA1 569/4885 |
| US-20260117070-A1 | NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES | CBR1, CBR3, NR2E3 | MME 2489/4885ACE 4520/4885CPA1 2372/4885 |
| US-20260069707-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES | CD22, CD2, CD44 | MME 965/4885ACE 2841/4885CPA1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.